Inaktiver Wert

Andere Sprachen Galena Biopharma Inc Nasdaq

Aktien

US3632561086

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

24.06.	SELLAS Life Sciences Group, Inc. gibt bekannt, dass die U.S. Food and Drug Administration (FDA) Sls009 den Status einer seltenen pädiatrischen Krankheit zur Behandlung der pädiatrischen akuten lymphoblastischen Leukämie zuerkannt hat	CI
17.06.	SELLAS Life Sciences Group, Inc. gibt positive Empfehlung des unabhängigen Datenüberwachungskomitees für die Phase 3 REGAL-Studie bei akuter myeloischer Leukämie bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	24.06.
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	24.06.
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	17.06.
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	17.06.
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML	10.06.
SELLAS Life Sciences Group, Inc. Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML	10.06.
Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	19.05.
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update	14.05.
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	01.05.
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	01.05.
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29.04.
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29.04.
North American Morning Briefing : Powell Awaited -2-	03.04.
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	28.03.
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	26.03.
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	26.03.
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	19.03.
Sector Update: Health Care Stocks Ease Late Afternoon	15.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Galena Biopharma Inc Nasdaq

Aktien

US3632561086

Andere Sprachen

Filter